Professur für Translationale Frauenheilkunde und Geburtshilfe

Update Breast Cancer 2024 Part 3 – Patients with Advanced Stage Breast Cancer (2025) Lüftner D, Kolberg HC, Hartkopf AD, Fehm TN, Welslau M, Müller V, Schütz F, et al. Journal article, Review article Update Breast Cancer 2024 Part 2 – Patients with Early Stage Breast Cancer (2025) Janni W, Kolberg HC, Hartkopf AD, Fehm TN, Welslau M, Müller V, Schütz F, et al. Journal article, Review article Effects of pregnancy on breast cancer immunology: immune biomarker and TIL quantification (2025) Galas K, Gleitsmann M, Rey J, Solbach C, Witzel I, Karn T, Schmatloch S, et al. Journal article Neoadjuvant Paclitaxel/Olaparib in Comparison to Paclitaxel/Carboplatin in Patients with HER2-Negative Breast Cancer and HRD-Long-term Survival of the GeparOLA Study (2025) Fasching P, Schmatloch S, Hauke J, Rey J, Jackisch C, Klare P, Link T, et al. Journal article Health-Related Quality of Life in Patients with HR+/HER2- Early Breast Cancer Treated with Ribociclib Plus a Nonsteroidal Aromatase Inhibitor: Results from the NATALEE Trial (2025) Fasching P, Slamon D, Nowecki Z, Kukielka-Budny B, Stroyakovskiy D, Yardley DA, Huang CS, et al. Journal article Patterns of Associations with Epidemiologic Factors by High-Grade Serous Ovarian Cancer Gene Expression Subtypes (2025) Collin LJ, Cushing-Haugen KL, Terry KL, Goode EL, Wu AH, Harris HR, Sasamoto N, et al. Journal article BRCA1/2 and Other Predisposition Genes in High-Risk Hormone Receptor+/Human Epidermal Growth Factor Receptor 2-Breast Cancer Treated with Endocrine Therapy with or Without Palbociclib: A Secondary PENELOPE-B Study Analysis (2025) Hahnen E, Hauke J, Gelmon K, Marmé F, Ernst C, Martin M, Untch M, et al. Journal article Fully automatic HER2 tissue segmentation for interpretable HER2 scoring (2025) Öttl M, Steenpaß J, Wilm F, Qiu J, Rübner M, Lang-Schwarz C, Taverna C, et al. Journal article Improving quality of care for cancer patients through oncological second opinions in a Comprehensive Cancer Center: adherence to second-opinion therapy recommendations (2025) Schulmeyer C, Fasching P, Beckmann M, Häberle L, Golcher H, Goebell P, Pöschke P, Emons J Journal article Characteristics and prognosis of patients with primary metastatic disease vs. recurrent HER2-negative, hormone receptor-positive advanced breast cancer (2025) Walter CB, Hartkopf AD, Hein A, Fasching P, Kolberg HC, Hadji P, Tesch H, et al. Journal article